Linked Life Data

2851312

Source:http://linkedlifedata.com/resource/pubmed/id/2851312

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2851312rdf:typepubmed:Citationlld:pubmed
pubmed-article:2851312lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:2851312lifeskim:mentionsumls-concept:C0003297lld:lifeskim
pubmed-article:2851312lifeskim:mentionsumls-concept:C0231491lld:lifeskim
pubmed-article:2851312lifeskim:mentionsumls-concept:C0733443lld:lifeskim
pubmed-article:2851312pubmed:issue5lld:pubmed
pubmed-article:2851312pubmed:dateCreated1989-3-16lld:pubmed
pubmed-article:2851312pubmed:abstractTextTwenty patients receiving a variety of emetogenic cytotoxics (including cisplatin in 5) were given a single i.v. infusion of 40 micrograms kg-1 of BRL43694 (as the hydrochloride salt) in successive groups of 3-4 patients between 0-6 hours after chemotherapy. Eleven patients were completely protected from vomiting; 9 had mild to moderate nausea and vomiting, but none severe enough to require alternative anti-emetic 'rescue'. In 4 of the patients in whom BRL43694 was delayed until 4-6 h after chemotherapy, vomiting had already begun; in each case immediate termination of vomiting occurred when BRL43694 was infused. No adverse effects attributable to the anti-emetic were observed. Mean pharmacokinetic parameters in 14 patients in whom plasma assay data are available were: Maximum observed concentration = 30.7 ng ml-1; terminal phase half-life = 8.96 h; total body clearance = 0.376 (1 h-1) kg-1; apparent volume of distribution = 2.85 l kg-1. This study shows BRL43694 to be an effective and well tolerated anti-emetic. Further studies aimed at defining an optimal dose and schedule for use against the most emetogenic cytotoxics are in progress.lld:pubmed
pubmed-article:2851312pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2851312pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2851312pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2851312pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2851312pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2851312pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2851312pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2851312pubmed:languageenglld:pubmed
pubmed-article:2851312pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2851312pubmed:citationSubsetIMlld:pubmed
pubmed-article:2851312pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2851312pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2851312pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2851312pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2851312pubmed:statusMEDLINElld:pubmed
pubmed-article:2851312pubmed:monthNovlld:pubmed
pubmed-article:2851312pubmed:issn0007-0920lld:pubmed
pubmed-article:2851312pubmed:authorpubmed-author:AdamsLLlld:pubmed
pubmed-article:2851312pubmed:authorpubmed-author:CassidyJJlld:pubmed
pubmed-article:2851312pubmed:authorpubmed-author:LewisCClld:pubmed
pubmed-article:2851312pubmed:authorpubmed-author:KayeS BSBlld:pubmed
pubmed-article:2851312pubmed:authorpubmed-author:SoukopMMlld:pubmed
pubmed-article:2851312pubmed:authorpubmed-author:RaineJJlld:pubmed
pubmed-article:2851312pubmed:authorpubmed-author:RankinE MEMlld:pubmed
pubmed-article:2851312pubmed:authorpubmed-author:ZussmanB DBDlld:pubmed
pubmed-article:2851312pubmed:authorpubmed-author:RapeportW GWGlld:pubmed
pubmed-article:2851312pubmed:issnTypePrintlld:pubmed
pubmed-article:2851312pubmed:volume58lld:pubmed
pubmed-article:2851312pubmed:ownerNLMlld:pubmed
pubmed-article:2851312pubmed:authorsCompleteYlld:pubmed
pubmed-article:2851312pubmed:pagination651-3lld:pubmed
pubmed-article:2851312pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:2851312pubmed:meshHeadingpubmed-meshheading:2851312-...lld:pubmed
pubmed-article:2851312pubmed:meshHeadingpubmed-meshheading:2851312-...lld:pubmed
pubmed-article:2851312pubmed:meshHeadingpubmed-meshheading:2851312-...lld:pubmed
pubmed-article:2851312pubmed:meshHeadingpubmed-meshheading:2851312-...lld:pubmed
pubmed-article:2851312pubmed:meshHeadingpubmed-meshheading:2851312-...lld:pubmed
pubmed-article:2851312pubmed:meshHeadingpubmed-meshheading:2851312-...lld:pubmed
pubmed-article:2851312pubmed:meshHeadingpubmed-meshheading:2851312-...lld:pubmed
pubmed-article:2851312pubmed:meshHeadingpubmed-meshheading:2851312-...lld:pubmed
pubmed-article:2851312pubmed:meshHeadingpubmed-meshheading:2851312-...lld:pubmed
pubmed-article:2851312pubmed:meshHeadingpubmed-meshheading:2851312-...lld:pubmed
pubmed-article:2851312pubmed:meshHeadingpubmed-meshheading:2851312-...lld:pubmed
pubmed-article:2851312pubmed:meshHeadingpubmed-meshheading:2851312-...lld:pubmed
pubmed-article:2851312pubmed:meshHeadingpubmed-meshheading:2851312-...lld:pubmed
pubmed-article:2851312pubmed:meshHeadingpubmed-meshheading:2851312-...lld:pubmed
pubmed-article:2851312pubmed:meshHeadingpubmed-meshheading:2851312-...lld:pubmed
pubmed-article:2851312pubmed:year1988lld:pubmed
pubmed-article:2851312pubmed:articleTitlePharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist.lld:pubmed
pubmed-article:2851312pubmed:affiliationCRC Department of Medical Oncology, Glasgow.lld:pubmed
pubmed-article:2851312pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2851312lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2851312lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2851312lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2851312lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2851312lld:pubmed